Raman Baweja, MD

New ADHD option Simtriyo gains FDA approval as first NDSRI, showing benefits for teens and adults, including executive function and emotional control.

FDA clears first triple reuptake ADHD drug Simtriyo, offering nonstimulant relief for adults and kids 6+ with executive and emotional symptoms.